Skip to main navigation
menu

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Drug Development Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Products
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Extras Menu

  • Media resources
  • Contact us

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Drug Development Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Products
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Investor Relations

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events
  • SEC Filings
  • Corporate Governance
  • Investor Presentations
  • Investor FAQs
  • Email Alerts
Investor Contact
For investor related questions, please email
investors@aclaristx.com

Press Releases

Press Releases

March 15, 2021
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
February 25, 2021
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
February 22, 2021
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
February 10, 2021
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
January 20, 2021
Aclaris Announces Pricing of Public Offering of Common Stock
January 19, 2021
Aclaris Announces Proposed Public Offering of Common Stock
January 19, 2021
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
Load More »

Aclaris - Footer Menu

  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Fraudulent Activity Notice
© 2021 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.